Table 4.
Short-term response effects of EGFR(+) and EGFR(−) patients in the active arm.
| EGFR in Adenocarcinoma | EGFR(+) (n = 10) |
EGFR(−) n = 13 |
P value* | |
|---|---|---|---|---|
| 19 (+) (n = 4) |
21 (+) (n = 6) |
|||
| 3-Month Response | ||||
| PR | 3 | 0 | 0 | 0.100 |
| SD | 1 | 2 | 3 | |
| PD | 0 | 4 | 10 | |
| 3-Month DCR (PR + SD) | 6 | 3 | 0.072 | |
| PFS (Median) | 3 (months) | 2.9 (months) | 0.805 | |
| OS (Median) | 21.8 (months) | 7.8 (months) | 0.253 | |
Abbreviations: PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; PFS, progression-free survival; OS, overall survival.
*
Response effects of EGFR(+) and EGFR(-) patients in the active arm were examined by χ2 test and T test; P < 0 0.05 indicates statistically significant difference.